An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy
Launched by BRISTOL-MYERS SQUIBB · Apr 25, 2012
Trial Information
Current as of June 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
- Key Inclusion Criteria:
- • Histologically confirmed, unresectable locally advanced or metastatic adenocarcinoma of the gastric and gastro-esophageal junction
- • Received first-line chemotherapy using fluoropyrimidine and platinum combination without disease progression
- • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- • Measurable disease by modified WHO criteria (unless complete response from previous chemotherapy)
- Key Exclusion Criteria:
- • Known Human Epidermal growth factor Receptor2 (HER2) positive status
- • Radiological evidence of brain metastases
- • History of severe autoimmune or immune mediated disease requiring prolonged immunosuppressive treatment
- • Inadequate hematologic, renal and hepatic function
About Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
New York, New York, United States
Miami Beach, Florida, United States
Taipei, , Taiwan
Hong Kong, , Hong Kong
Houston, Texas, United States
Padova, , Italy
New York, New York, United States
Nice Cedex 03, , France
Mainz, , Germany
Roma, , Italy
Rennes, , France
Krakow, , Poland
Toulouse Cedex 09, , France
Singapore, , Singapore
Madrid, , Spain
Montpellier Cedex, , France
Olsztyn, , Poland
Firenze, , Italy
Pisa, , Italy
Milano, , Italy
Osaka Sayama Shi, Osaka, Japan
Nagoya, Aichi, Japan
Moscow, , Russian Federation
Lodz, , Poland
Gyeonggi Do, , Korea, Republic Of
Seoul, , Korea, Republic Of
Barcelona, , Spain
Saku Shi, Nagano, Japan
Kitaadachi Gun, Saitama, Japan
Katowice, Ochojec, Poland
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials